Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
COSMOS PharmaceuticalCSMYF 93 EBIT per Share is $3.68 as of Feb. 2026. GuruFocus rates CSMYF with a GF Score™ of 93/100 and a GF Value™ of $51.79 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 527 Healthcare Providers & Services companies, COSMOS Pharmaceutical ranks worse than 51.8% on this metric.
COSMOS Pharmaceutical's EBIT per Share for the
three
months ended in Feb. 2026 was $0.98.
Its EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2026 was $3.68.
During the past 12 months, the average EBIT per Share Growth Rate of COSMOS Pharmaceutical was 13.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 10.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 4.40% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 7.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for COSMOS Pharmaceutical's EBIT per Share or its related term are showing as below:
CSMYF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -4 Med: 10 Max: 34.8
Current: 10.7
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of COSMOS Pharmaceutical was 34.80% per year. The lowest was -4.00% per year. And the median was 10.00% per year.
CSMYF's 3-Year EBIT Growth Rate is ranked worse than 51.8% of 527
companies
in the Healthcare Providers & Services industry
Industry Median: 12.1
vs CSMYF: 10.70
COSMOS Pharmaceutical (OTCPK:CSMYF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
COSMOS Pharmaceutical EBIT per Share Related Terms
COSMOS Pharmaceutical EBIT per Share Historical Data
* Premium members only.
The historical data trend for COSMOS Pharmaceutical's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.68
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical (CSMYF) has a EBIT per Share of $3.68 as of Feb. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on COSMOS Pharmaceutical and its competitors. According to the industry distribution chart, COSMOS Pharmaceutical ranks #273 out of 527 companies in the Healthcare Providers & Services industry, placing it in the top 51.8%.
Is COSMOS Pharmaceutical's EBIT per Share too high?
COSMOS Pharmaceutical's current EBIT per Share is $3.68. The Healthcare Providers & Services industry median EBIT per Share is 12.10. COSMOS Pharmaceutical's value of $3.68 is 69.6% below this industry median. Based on the distribution chart, COSMOS Pharmaceutical ranks #273 out of 527 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, COSMOS Pharmaceutical has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's EBIT per Share compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, COSMOS Pharmaceutical ranks #273 out of 527 companies for EBIT per Share. This places COSMOS Pharmaceutical in the lower half of its industry. The industry median EBIT per Share is 12.10. COSMOS Pharmaceutical's value of $3.68 is 69.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.10, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. COSMOS Pharmaceutical's current EBIT per Share of $3.68 is 69.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on COSMOS Pharmaceutical and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. COSMOS Pharmaceutical's current EBIT per Share is $3.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, COSMOS Pharmaceutical (CSMYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $51.79, compared to a current price of $37.06 — trading 28.4% below its estimated fair value. The current EBIT per Share is $3.68 and 69.6% below the Healthcare Providers & Services industry median of 12.10. COSMOS Pharmaceutical's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current EBIT per Share is $3.68 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?
Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued.
The current stock price of $37.06 is trading 28.4% below its estimated GF Value™ of $51.79.
GuruFocus considers COSMOS Pharmaceutical to be Modestly Undervalued.
Key valuation signals for CSMYF:
EBIT per Share: $3.68
GF Value™: $51.79 vs. price of $37.06 (28.4% below fair value)
Industry Position: 69.6% below the Healthcare Providers & Services median (#273 of 527)
No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
93GF Score
Get the complete analysis for CSMYF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSMYF has been successfully added to your 
